Enzyme Inhibitors Or Activators Patents (Class 435/69.2)
-
Patent number: 7592420Abstract: Described herein are protease inhibitors, variants thereof and methods for their production.Type: GrantFiled: August 30, 2007Date of Patent: September 22, 2009Assignee: Genencor International, Inc.Inventors: Hans De Nobel, David A. Estell, Wei Liu, Scott D. Power, Brian Schmidt, Huaming Wang
-
Patent number: 7588901Abstract: The invention provides methods and compositions for modulating angiogenesis in a subject. The methods of modulating angiogenesis in a subject include administering to the subject a modulator of N-terminal arginylation activity. The invention also provides a method of identifying such a modulator and a method of in vitro screening for modulators of N-terminal arginylation activity. Additionally, the invention provides a method of treating an angiogenesis-related disorder.Type: GrantFiled: June 22, 2006Date of Patent: September 15, 2009Assignee: California Institute of TechnologyInventors: Yong Tae Kwon, Anna Kashina, Alexander Varshavsky
-
Patent number: 7582448Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.Type: GrantFiled: November 7, 2006Date of Patent: September 1, 2009Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Daniel E. H. Afar, Pia M. Challita-Eid, Elena Levin, Steven Chappell Mitchell, Rene S. Hubert
-
Patent number: 7575888Abstract: It is now discovered that human chymase cleaves human SLPI at a specific site and that this cleavage can be used as an indicator of chymase activity. The present invention provides methods of diagnosing a chymase-associated disease or evaluating the efficiency of a treatment of a chymase-associated disease in a human subject by measuring SLPI processing, as well as other related methods and compositions.Type: GrantFiled: January 12, 2007Date of Patent: August 18, 2009Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Stanley Belkowski, Michael R. D'Andrea
-
Patent number: 7575885Abstract: Tyrosylprotein sulfotransferases and nucleic acids encoding the tyrosylprotein sulfotransferases are described. Dual isotopes of the enzyme and of the nucleic acids encoding said enzymes have been identified in human, mouse and C. elegans. The polypeptides and polynucleotides exhibit a wide range of homologies. The polynucleotides can be used to transform or transfect host cells for producing substantially pure forms of the enzyme, or for use in an expression system for post-translational tyrosine sulfation of proteins or peptides produced within the expression system. The enzymes can be used to sulfate peptides or proteins requiring sulfation.Type: GrantFiled: January 3, 2008Date of Patent: August 18, 2009Assignee: Siwa Biotech CorporationInventor: Kevin L Moore
-
Patent number: 7569536Abstract: The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.Type: GrantFiled: December 24, 2004Date of Patent: August 4, 2009Inventors: Masatoshi Hagiwara, Takeshi Fukuhara, Masaaki Suzuki, Takamitsu Hosoya
-
Patent number: 7560248Abstract: Mutant forms of ribonuclease inhibitor are described which are rendered more resistant to oxidation while retaining affinity for both ribonuclease and angiogenin. The mutant forms have another amino acid, typically an alanine, substituted for one or more of the adjacent cysteine residues in the wild-type sequence to prevent the formation of unwanted disulfide bonds which can disrupt the effectiveness of the molecule.Type: GrantFiled: January 20, 1999Date of Patent: July 14, 2009Assignee: Wisconsin Alumni Research FoundationInventor: Ronald T. Raines
-
Patent number: 7553832Abstract: The present invention relates to compositions (i.e., various organic small molecules as exemplified herein) and methods for the inhibition of protein splicing and especially relates to the inhibition of protein autosplicing of intein-containing proteins. Additionally, the present invention relates to the use of the inhibitors of protein splicing of the invention for the treatment of various diseases including but not limited to tuberculosis. Furthermore, the invention provides the first instance of small molecule inhibitors of protein splicing with drug-like characteristics.Type: GrantFiled: January 24, 2006Date of Patent: June 30, 2009Assignee: Boston Biomedical Research InstituteInventor: Henry Paulus
-
Patent number: 7553614Abstract: Spectrophotometric assays are rendered more sensitive by adding to the assay mixture a light-emitting moiety. The decrease in intensity of light emitted due to the presence of a light-absorbing moiety associated with the photometric assay is much more sensitive to analyte than the absorbance of the light-absorbing moiety itself.Type: GrantFiled: February 9, 2004Date of Patent: June 30, 2009Inventor: Robert W. Brocia
-
Patent number: 7534592Abstract: Provided are crystals relating to the carboxyltransferase domain of human Acetyl-Coenzyme A Carboxylase 2 and its various uses.Type: GrantFiled: March 28, 2006Date of Patent: May 19, 2009Assignee: Takeda San Diego, Inc.Inventors: Douglas R. Dougan, Clifford D. Mol, Bi Ching Sang, Gyorgy Snell, Hua Zou
-
Patent number: 7534582Abstract: A method for accurately measuring an amount of natriuretic peptides in a sample that has stood for at least 24 hours, in a plastic tube or a tube coated with silicone. This method makes it possible to measure natriuretic peptides stably and conveniently. Also provided is a method for measuring the amount of natriuretic acid in a sample at the time of collection by measuring the amount of natriuretic peptide in a blood sample at two periods of time after collection.Type: GrantFiled: April 17, 2007Date of Patent: May 19, 2009Assignee: Shionogi & Co., Ltd.Inventors: Hiroyuki Shimizu, Hidehisa Asada, Kazuaki Endo
-
Patent number: 7527936Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.Type: GrantFiled: January 13, 2005Date of Patent: May 5, 2009Assignee: Rigel Pharmaceuticals Inc.Inventors: Weiduan Xu, Sacha J. Holland, James Lorens
-
Publication number: 20090088370Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.Type: ApplicationFiled: March 29, 2006Publication date: April 2, 2009Applicant: Octapharma AGInventor: Stefan Winge
-
Patent number: 7494784Abstract: The present invention relates to methods of identifying agents which modulate the activity of PIPKI?661. Methods of using such agents to prevent or treat a cell migration-mediated condition or disease in a subject are also provided.Type: GrantFiled: December 6, 2007Date of Patent: February 24, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Richard A. Anderson, Kun Ling
-
Patent number: 7476526Abstract: The invention relates to a gene isolated from E. coli, dep, which confers resistance to the antibacterial activity of 4,5-dihydroxy-2-cyclopenten-1-one (DHCP). The invention further relates to the putative protein encoded by dep, which is a hydrophobic, transmembrane efflux protein specific for DHCP. The invention further relates to plasmids containing the dep gene, and to bacterial cells expressing dep. Furthermore, the invention provides applications for use in conferring resistance to antibacterial activity in organisms. The dep gene can be used to identify compounds which inhibit the efflux activity responsible for the resistance to DHCP or to compounds which are functionally equivalent to DHCP.Type: GrantFiled: September 12, 2005Date of Patent: January 13, 2009Assignee: Takara Bio Inc.Inventors: Sangita Phadtare, Kunitoshi Yamanaka, Ikunoshin Kato, Masayori Inouye
-
Patent number: 7465564Abstract: The present invention relates to methods for the production of ?-linolenic acid (GLA) in oleaginous yeast. Thus, ?12 and ?6 desaturases able to catalyze the conversion of oleic acid to GLA have been introduced into the genome of Yarrowia, using zeta-directed integration. Transformed strains produced over 25% GLA in the total lipids, as opposed to wildtype Yarrowia that is unable to synthesize any GLA. Metabolic engineering and fermentation methods are provided to further enhance GLA productivity in oleaginous yeast.Type: GrantFiled: August 8, 2005Date of Patent: December 16, 2008Assignee: E.I. du Pont de Nemours and CompanyInventors: Quinn Qun Zhu, Dana M. Walters Pollak
-
Publication number: 20080305525Abstract: Disclosed are a novel Hansenula polymorpha gene coding for ?-1,6-mannosyltransferase initiating outer chain elongation in N-linked glycosylation, an H. polymorpha mutant strain having a deficiency in the gene, and a process for producing recombinant glycoprotein using such a mutant strain.Type: ApplicationFiled: July 21, 2004Publication date: December 11, 2008Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Hyun-Ah Kang, Moo-Woong Kim, Sang-Ki Rhee, Joo Hyung Heo
-
Patent number: 7462695Abstract: The present invention relates generally to a novel chymotrypsin that exhibits resistance to a plant serine proteinase inhibitor. More particularly, the present invention provides a chymotrypsin which is up-regulated in the gut of Helicoverpa armigera and Helicoverpa punctigera insect larvae when fed the serine proteinase inhibitors of Nicotiana alata. The novel chymotrypsin represents, therefore, a target for the identification of antagonists including inhibitors which are proposed to be useful in the control of Helicoverpa spp. populations that have become resistant to serine proteinase inhibitors produced in plants. The antagonists of the chymotrypsin may be topically applied to the plants or, when in proteinaceous form, may be produced by genetic means in plant cells. The antagonists may act at the level of gene expression or protein activity.Type: GrantFiled: April 23, 2004Date of Patent: December 9, 2008Assignee: Hexima LimitedInventors: Kerry Michelle Dunse, Robyn Louise Heath, Marilyn Anne Anderson
-
Patent number: 7462472Abstract: The structures of Edema Factor alone and Edema Factor bound to calmodulin without substrate has been crystallized and its structure determined by x-ray crystallography. Based upon these crystal structures, a method assaying for inhibitors of infection by a bacteria is presented which comprises obtaining a potential inhibitor, obtaining a calmodulin activated adenylyl cyclase exotoxin, obtaining calmodulin, admixing the potential inhibitor, the exotoxin, and the calmodulin, and assaying to determine whether or not the potential inhibitor inhibits production of cAMP by exotoxin.Type: GrantFiled: November 1, 2002Date of Patent: December 9, 2008Assignees: The University of Chicago, Boston Biomedical Research InstituteInventors: Wei-Jen Tang, Andrew Bohm
-
Publication number: 20080299616Abstract: The present invention relates to the isolation of DNA regulatory regions of the malate synthase 1 gene (MLS1) from the yeast, Pichia pastoris. The present invention further relates to the expression of heterologous proteins which have been introduced into a P. pastoris host cell and can be expressed under the regulation of the MLS1 5? regulatory promoter and MLS1 3?regulatory terminator regions. The MLS1 promoter is repressed in media containing glucose and derepressed under glucose starvation conditions or when acetate is present.Type: ApplicationFiled: July 22, 2005Publication date: December 4, 2008Inventor: Byung-Kwon Choi
-
Patent number: 7449309Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.Type: GrantFiled: December 20, 2005Date of Patent: November 11, 2008Assignee: The Trustees of Columbia University in the City of New YorkInventor: B. Jack Longley
-
Publication number: 20080255025Abstract: Proteins including engineered sequences which inhibit proteases are disclosed, including proteins having two or more engineered Kunitz domains, and uses of such proteins.Type: ApplicationFiled: December 27, 2006Publication date: October 16, 2008Inventor: Robert C. Ladner
-
Patent number: 7422890Abstract: A phospholipase A2 inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases.Type: GrantFiled: November 30, 2005Date of Patent: September 9, 2008Assignee: National University of SingaporeInventors: Ponnampalam Gopalakrishnakone, Maung-Maung Thwin, Kandiah Jeyaseelan, Arunmozhiarasi Armugam
-
Patent number: 7399606Abstract: The present invention provides methods and compositions for inhibiting I?B Kinase (IKK) as well as methods and compositions for identifying compounds with activity as inhibitors of IKK. In particular, the present invention provides methods for identifying inhibitors of IKK?.Type: GrantFiled: February 8, 2006Date of Patent: July 15, 2008Assignee: The Regents of the University of CaliforniaInventors: Michael Karin, Pankaj Kapahi
-
Patent number: 7399605Abstract: The present invention relates to the molecular biology and virology of the hepatitis C virus (HCV). An object of the present invention is a method to reproduce in vitro the RNA-dependent RNA polymerase activity of HCV that makes use of sequences contained in the HCV NS5B protein.Type: GrantFiled: February 27, 2002Date of Patent: July 15, 2008Assignee: Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.Inventors: Raffaele De Francesco, Licia Tomei, Sven-Erik Behrens
-
Patent number: 7396659Abstract: A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of at least one inhibitor of inducible nitric oxide synthase or a pro-inflammatory cytokine, wherein the inhibitor is an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof, and the inhibitor specifically inhibits the activity of HMG-CoA reductase.Type: GrantFiled: August 15, 2005Date of Patent: July 8, 2008Assignee: Musc Foundation for Research DevelopmentInventor: Inderjit Singh
-
Patent number: 7384907Abstract: The present invention relates to a method of preventing or treating a pathogen infection comprising administering to a mammal in need thereof an effective amount of an inhibitor of Abl tyrosine kinase.Type: GrantFiled: December 15, 2003Date of Patent: June 10, 2008Assignee: Duke UniversityInventors: Ann Marie Pendergast, Elizabeth A. Burton
-
Publication number: 20080131932Abstract: Described herein are protease inhibitors, variants thereof and methods for their production.Type: ApplicationFiled: August 30, 2007Publication date: June 5, 2008Inventors: Hans De Nobel, David A. Estell, Wei Liu, Scott D. Power, Brian Schmidt, Huaming Wang
-
Patent number: 7381537Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screeing for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.Type: GrantFiled: May 5, 2004Date of Patent: June 3, 2008Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre J. Niestroj, Stephan Schilling, Ulrich Heiser
-
Publication number: 20080113408Abstract: Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.Type: ApplicationFiled: October 30, 2007Publication date: May 15, 2008Applicant: AMBRX, INC.Inventors: Roberto MARIANI, Bruce E. KIMMEL
-
Publication number: 20080112943Abstract: Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.Type: ApplicationFiled: October 30, 2007Publication date: May 15, 2008Applicant: AMBRX, INC.Inventors: Roberto MARIANI, Bruce E. KIMMEL
-
Patent number: 7369946Abstract: The present invention relates to polypeptides which comprise the ligand binding domain of Tie-2, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Tie-2. The invention also relates to the use of the three dimensional structure of the Tie-2 catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Tie-2 activity, for example, compounds which inhibit the binding of a native substrate to the Tie-2 catalytic domain.Type: GrantFiled: March 22, 2001Date of Patent: May 6, 2008Assignee: Abbott GmbH & Co. KGInventors: Nancy J. Bump, Lee D. Arnold, Richard W. Dixon, Hans Wolfgang Hoeffken, Karen Allen, Cornelia Bellamacina
-
Patent number: 7368551Abstract: De novo DNA cytosine methyltransferase polynucleotides and polypeptides and methods for producing said polypeptides are disclosed. Also disclosed are methods for utilizing de novo DNA cytosine methyltransferase polynucleotides and polypeptides in diagnostic assays, in vitro DNA methylation assays for screening agonists and antagonists, and therapeutic applications such as the treatment of neoplastic disorders.Type: GrantFiled: July 22, 2003Date of Patent: May 6, 2008Assignee: The General Hospital CorporationInventors: En Li, Masaki Okano, Shaoping Xie, Taiping Chen
-
Patent number: 7364910Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: GrantFiled: July 6, 2006Date of Patent: April 29, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
-
Patent number: 7342108Abstract: De novo DNA cytosine methyltransferase polynucleotides and polypeptides and methods for producing said polypeptides are disclosed. Also disclosed are methods for utilizing de novo DNA cytosine methyltransferase polynucleotides and polypeptides in diagnostic assays, for an in vitro DNA methylation application and therapeutic applications such as the treatment of neoplastic disorders.Type: GrantFiled: June 25, 1999Date of Patent: March 11, 2008Assignee: The General Hospital CorporationInventors: En Li, Masaki Okano, Shaoping Xie
-
Patent number: 7335492Abstract: The present invention relates to isolation and purification of protein in aqueous two-phase systems (ATPS). Specifically, the invention provides processes for partitioning of proteins of interest in ATPS by fusing said proteins to targeting proteins which have the ability of carrying said protein into one of the phases.Type: GrantFiled: October 19, 2005Date of Patent: February 26, 2008Assignee: Valtion Teknillinen TutkimuskeskusInventors: Merja Penttilä, Tiina Nakari-Setälä, Richard Fagerström, Klaus Selber, Maria-Regina Kula, Markus Linder, Folke Tjerneld
-
Patent number: 7316912Abstract: Tyrosylprotein sulfotransferases and nucleic acids encoding the tyrosylprotein sulfotransferases are described. Dual isotopes of the enzyme and of the nucleic acids encoding said enzymes have been identified in human, mouse and C. elegans. The polypeptides and polynucleotides exhibit a wide range of homologies. The polynucleotides can be used to transform or transfect host cells for producing substantially pure forms of the enzyme, or for use in an expression system for post-translational tyrosine sulfation of proteins or peptides produced within the expression system. The enzymes can be used to sulfate peptides or proteins requiring sulfation.Type: GrantFiled: January 20, 2006Date of Patent: January 8, 2008Assignee: Siwa Biotech CorporationInventor: Kevin L. Moore
-
Patent number: 7311907Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.Type: GrantFiled: April 5, 2005Date of Patent: December 25, 2007Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 7306938Abstract: Methods for identifying compounds that are inhibitors of bacterial fatty acid biosynthesis are disclosed. Such compounds can be used as lead compounds in methods for preparing antibacterial agents for treating bacterial infections (e.g., in humans, animals, and plants). Inhibitors of bacterial fatty acid synthesis can also be tested for their ability to inhibit synthesis of acylated homoserine lactones. Compounds that inhibit synthesis of acylated homoserine lactones can be used as inhibitors of bacterial virulence. The disclosed methods allow for high throughput screening of libraries of test compounds.Type: GrantFiled: October 10, 2003Date of Patent: December 11, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher Murphy, Philip Youngman
-
Patent number: 7297514Abstract: A method of reducing superoxide damage to a cell is disclosed. In one embodiment, this method comprises the step of engineering the cell to produce more than a native amount of the YggX protein or its homolog, wherein the cells are rendered more resistant to superoxide damage.Type: GrantFiled: September 18, 2001Date of Patent: November 20, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Diana Downs, Jeff A. Gralnick
-
Patent number: 7285406Abstract: The invention relates to the isolation, sequencing, and recombinant expression of genes encoding either a nitrile hydratase (NHase) or amidase (Am) from Comamonas testosteroni 5-MGAM-4D, where the NHase is useful for catalyzing the hydration of nitrites to the corresponding amides, and the amidase is useful for hydrolysis of amides to the corresponding carboxylic acids. Also provided are transformed host cells containing polynucleotides for expressing the nitrile hydratase or amidase enzymes from Comamonas testosteroni 5-MGAM-4D.Type: GrantFiled: November 16, 2006Date of Patent: October 23, 2007Assignee: E.I. du Pont de Nemours and CompanyInventors: Mark S. Payne, Robert DiCosimo, John E. Gavagan, Robert D. Fallon
-
Patent number: 7282325Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.Type: GrantFiled: February 25, 2004Date of Patent: October 16, 2007Assignee: Solvay Pharmaceuticals GmbHInventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
-
Patent number: 7279302Abstract: The invention concerns novel enzymes having an arogenate dehydrogenase activity, in particular arogenate dehydrogenase enzymes of plants, and the genes encoding said enzymes. The inventive arogenate dehydrogenase enzymes catalyze the last stage of the metabolic pathway of tyrosine biosynthesis, and constitute, as such, potential targets of herbicides. Hence the invention also concerns a method for identifying herbicide compounds targeting said enzymes, said herbicide compounds preventing tyrosine biosynthesis by being fixed on said enzymes. The invention further concerns transgenic plants tolerant to herbicide compounds targeting an enzyme involved in the tyrosine biosynthesis pathway, in particular an enzyme involved in the transformation of L-tyrosine prephenate, in particular an arogenate dehydrogenase enzyme.Type: GrantFiled: December 5, 2001Date of Patent: October 9, 2007Assignee: Bayer CropScience S.A.Inventors: Michel Matringe, Pascal Rippert
-
Patent number: 7276348Abstract: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.Type: GrantFiled: March 8, 2004Date of Patent: October 2, 2007Assignee: Regents of the University of MichiganInventor: Gary D. Glick
-
Patent number: 7270979Abstract: Alpha 1-antitrypsin is prepared by growing in a fermentor methylotropic yeast transformants containing in their genome at least one copy of DNA encoding alpha 1-antitrypsin, in operational linkage with DNA encoding a signal sequence, which is effective for directing secretion of proteins from the host cells, DNA constructs and recombinant yeast strains used for the expression and secretion of alpha 1-antritrypsin are also provided. The fermentation medium requires a pH of 6.5 to 7.5. The fermentation is at a pH between 5 and 6.8.Type: GrantFiled: September 26, 2003Date of Patent: September 18, 2007Assignee: Alphamed Pharmaceuticals CorpInventors: John Lezdey, K. Anne Kronis, Darren Lezdey
-
Patent number: 7264809Abstract: The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.Type: GrantFiled: October 13, 1999Date of Patent: September 4, 2007Assignees: Immunex Corporation, Cornell Research Foundation, Inc.Inventors: Richard B. Gayle, III, Aaron J. Marcus, Charles R. Maliszewski
-
Patent number: 7258984Abstract: A nucleic acid sequence which regulates the autolytic activity of bacteria is provided. Methods for identifying and using agents which interact with the gene to inhibit bacterial growth and infectivity also are provided.Type: GrantFiled: June 14, 2005Date of Patent: August 21, 2007Assignee: Trustees of Dartmouth CollegeInventor: Ambrose Cheung
-
Patent number: 7256267Abstract: The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: January 11, 2006Date of Patent: August 14, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Jian Chen, Thomas Nelson, Donna A Bassolino, Daniel L. Cheney
-
Patent number: 7256013Abstract: The acetylation level of a peptide is determined utilizing the fact that the changes in the acetylation level are reflected in the sensitivity of the substrate peptide to a peptidase. This method can be used for measuring activities of deacetylase and acetylase, and also enables screening for substances that influence the activity of these enzymes. The deacetylase activity can be measured by a simple procedure according to the present invention.Type: GrantFiled: October 31, 2005Date of Patent: August 14, 2007Assignee: Cyclex Co., Ltd.Inventors: Katsuyuki Tamai, Toshiaki Miyazaki, Emi Wada, Ayumi Tatsuzawa
-
Patent number: 7256028Abstract: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase.Type: GrantFiled: October 26, 2001Date of Patent: August 14, 2007Assignee: Xenon Genetics Inc.Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka